PAVmed is a medical technology company organized to advance a pipeline of medical technologies from concept to commercialization. Co.'s EsoGuard and EsoCheck have been developed to provide a screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplastic BE and related pre-cursors to EAC in patients with chronic gastroesophageal reflux. Co.'s EsoCure is in development as an Esophageal Ablation Device, with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC, a lethal esophageal cancer. Co.'s CarpX is a minimally invasive surgical device for use in the treatment of carpal tunnel syndrome. The PAVM average annual return since 2016 is shown above.
The Average Annual Return on the PAVM average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PAVM average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PAVM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|